Shots:
- Zymeworks secured $250M from Royalty Pharma via a non-recourse royalty-backed note, repayable from 30% of worldwide tiered royalties on Ziihera owed by Jazz Pharmaceuticals and BeOne Medicines
- Royalty will receive payments until it achieves 1.65x of the note by Dec 31, 2033, or 1.925x thereafter; Zymeworks retains 70% of royalties during repayment, with full royalty rights reverting post-repayment
- Zymeworks also remains eligible for 10% to high teens on global sales of up to $2B (ex-Asia, Australia & NZ) & 20% on >$2B sales via Jazz, & mid-single to mid-double digits on sales up to $1B plus 19.5% >$1B via BeOne, alongside up to $1.5B in remaining regulatory & commercial milestonesÂ
Ref: Zymeworks|  Image: Zymeworks & Royalty Pharma | Press Release
Related News: Teva and Royalty Pharma Enter Funding Agreement to Accelerate TEV-’408 Development in Vitiligo
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
